| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2018-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fec267766f250095df1cf683001fb3f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6189bc0ee53c2cba5ca81fff26121764 |
| publicationDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110662559-A |
| titleOfInvention |
Compositions and methods for targeting and killing ALPHA-V BETA-3(αvβ3)-positive cancer stem cells (CSCs) and treating drug-resistant cancers |
| abstract |
Compositions and methods for treating or alleviating cancer are provided by killing CSCs by targeting ALPHA-V BETA-3 polypeptides expressed on the cell surface of cancer stem cells (CSCs), thereby treating treatment by ALPHA-V BETA-3 polypeptides expressed on their cell surfaces. Cancer cells or tumor cells of a V BETA-3 polypeptide, or cancer stem cells cause or initiate, or are maintained by, cancer. Compositions and methods are provided for targeting and killing ALPHA-V BETA-3 positive cancer stem cells (CSCs) and treating drug-resistant cancers. In alternative embodiments, the compositions and methods provided herein employ antibodies capable of specifically binding human ALPHA-V BETA-3, which also include antibodies capable of mediating antibody-dependent cell-mediated Cytotoxicity (ADCC) kills the Fc portion of cancer cells by macrophages; eg, using a humanized antibody against ALPHA-V BETA-3, modified to include engineered. |
| priorityDate |
2017-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |